Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
21 Novembro 2023 - 10:01AM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced that Ardelyx management will participate in a
fireside chat at the Piper Sandler 35th Annual Healthcare
Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in
New York City.
To access the live webcast of Ardelyx's session,
please visit the Events & Presentations page within the
Investor section of the Ardelyx website at ir.ardelyx.com. A replay
of the webcast will be available on the Ardelyx website for 30 days
following the event.
About Ardelyx, Inc.Ardelyx was
founded with a mission to discover, develop and commercialize
innovative, first-in-class medicines that meet significant unmet
medical needs. Ardelyx has two commercial products approved in the
United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor), as
well as early-stage pipeline candidates. Ardelyx has agreements for
the development and commercialization of tenapanor outside of the
U.S. Kyowa Kirin has received approval for PHOZEVEL® (tenapanor)
for hyperphosphatemia in Japan. A New Drug Application for
tenapanor for hyperphosphatemia has been submitted in China with
Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada.
For more information, please visit https://ardelyx.com/ and connect
with us on X (formerly known as Twitter), LinkedIn and
Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Ardelyx (NASDAQ:ARDX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024